Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Net Cash Flow (2024 - 2026)

Evommune (EVMN) reported Net Cash Flow of $4.2 million for Q1 2026, up 140.27% year-over-year from $1.8 million in Q1 2025, and down 75.37% on a QoQ basis from $17.2 million in Q4 2025.

Evommune (EVMN) has 3 years of Net Cash Flow data on file, last reported at $4.2 million in Q1 2026.

  • Quarterly Net Cash Flow rose 140.27% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (changed N/A YoY) and the FY2025 annual result came in at $29.0 million, up 327.23% from the prior year.
  • Net Cash Flow eased to $4.2 million in Q1 2026 per EVMN's latest filing, from $17.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $17.2 million in Q4 2025 and bottomed at -$10.6 million in Q1 2025.
  • The 3-year median for Net Cash Flow is $1.2 million (2024), against an average of $2.3 million.
  • The widest annual swing landed in 2025, when Net Cash Flow soared 1012.11%; it then soared 140.27% in 2026.
  • Tracing EVMN's Net Cash Flow over 3 years: stood at -$1.9 million in 2024, then soared by 1012.11% to $17.2 million in 2025, then tumbled by 75.37% to $4.2 million in 2026.
  • Per Business Quant, the three latest EVMN Net Cash Flow figures stand at $4.2 million (Q1 2026), $17.2 million (Q4 2025), and -$10.6 million (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.44 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 625.70 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.44 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 457.40 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -152.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 60.68 Mn
10 Evommune 744.11 Mn 532.65 Mn - 4.25 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 4.25 Mn
Mar 31, 2026 4.25 Mn
Dec 31, 2025 17.25 Mn
Dec 31, 2025 17.25 Mn
Mar 31, 2025 -10.55 Mn
Mar 31, 2025 -10.55 Mn
Dec 31, 2024 -1.89 Mn
Dec 31, 2024 -1.89 Mn